ERBB2 and ovarian carcinoma: In September 2023, the team of Tu Jiajie, Institute of Clinical Pharmacology, Anhui Medical University, constructed HER2-targeting CAR-Ms and CD47-targeting CAR-Ms, and co-cultured them with antigen-positive ovarian cancer cells in vitro.